


# **ESMO Preceptorship Programme**


Prague, April 2017













## **Ovarian Cancer Preceptorship Course**

European Society for Medical Oncology

- Small percentage of total cancers
- Specialist knowledge
- International collaboration
  - European
    - ESMO
    - ESGO
    - ENGOT
  - Global
    - ASCO
    - IGCS
    - GCIG

## Faculty

- Jonathan Ledermann (UK)
- Susana Banerjee (UK)
- Nicoletta Colombo (Italy)
- Christina Fotopoulou (UK)
- Christian Marth (Austria)
- Glenn McCluggage (UK)
- Iain McNeish (UK)
- Mansoor Mirza ( Denmark)
- Andrés Poveda (Spain)
- Isabelle Ray-Coquard (France)
- Cristiana Sessa (Switzerland)



# **Uncommon but complex!**

- Not one disease- pathology and biology very different
- Multi-disciplinary surgery and drug therapy
- Unusually responsive to chemotherapy
- Some patients presenting with advanced disease are cured!
- Often responsive to multiple lines of therapy
- Excellent test-bed for novel therapies
- Patients may live for several years after initial presentation
- Complex management of end-stage disease



### **ESMO** Resources

European Society for Medical Oncology



More



## **Oncology Pro**

European Society for Medical Oncology

### **PARP Inhibitors: Current ar**

### ESMO E-Learn Chemotherapy

Date: 03 Apr 2017 Topic: Ovarian Cancer

Speaker: Thomas Halleday

#### Learning Objectives

- 1. To provide an update
- 2. To provide a summa intraperitoneal cherr
- To provide key informanagement of ova



#### **Ovarian Cancer IP Cher**

In th chei

pivo

feat evid

of p

intra

In th

mar

obta

FIG



Pierfranco Conte **Read more** 



#### Prof. Thomas Helleday's mainly focused on under DNA-damage signalling ESMO Symposium on S 2017, where he spoke ab inhibitors and what w

## Advanced Ovarian Cancer Optimal Therapy. Update

# **Remarks and Conclusions**

Andrés Poveda

Instituto Valenciano de Oncología, Valencia, Spain

Discussion Points



- Aims
- Ovarian Cancer- Pathology and Biology
  - Underpins our knowledge and drives therapeutic research
- Surgery
  - Key aspects for medical oncologists
- The importance of multidisciplinary management
  - Choosing the right therapy for the right patient at the right time
  - First-line therapy and choices
  - Complexities of managing recurrent ovarian cancer
  - Interdisciplinary interaction
- Decision-making
  - Understanding the evidence-base developed from clinical trials
  - Increasing complexity of trial design
  - Novel methods to evaluate new drugs- molecular therapeutics and immunotherapy
  - Management of patient symptoms and side-effects of treatment